| Symbol | COSM |
|---|---|
| Name | COSMOS HEALTH INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Other Pharmaceuticals |
| Address | 141 WEST JACKSON BOULEVARD,SUITE 4236, CHICAGO, Illinois, 60604, United States |
| Telephone | +1 312 536-3102 |
| Fax | — |
| — | |
| Website | https://www.cosmoshealthinc.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001474167 |
| Description | Cosmos Health Inc. is a global healthcare company. The Company owns a portfolio of pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe and C-Sept. Through its subsidiary, Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It distributes a line of pharmaceuticals and Para pharmaceuticals, including branded generics and over the counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It is also engaged in the research and development (R&D) of patented nutraceuticals and specialized root extracts as well as in the R&D of complex generics and OTC products. It offers Cloudscreen, a multimodal platform specialized in drug repurposing, a process of uncovering new target proteins. It is also specialized in the storage and distribution of pharmaceutical and Para pharmaceutical goods. Additional info from NASDAQ: |
Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months
Read moreNew Form SCHEDULE 13G/A - Cosmos Health Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0002059371-26-000005 <b>Size:</b> 6 KB
Read moreNew Form S-3/A - Cosmos Health Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001477932-26-002526 <b>Size:</b> 519 KB
Read moreCosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products
Read moreCosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product Portfolio
Read moreCosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering39× Higher Bioavailability and Designed to Support Joint Health
Read moreCosmos Health Advances AI Investments to Enhance Efficiency, Reduce Costs, Improve Customer Experience and Drive Sales Growth; Certain Operating Expenses May Decrease by Up to 30%
Read more(80% Positive) COSMOS HEALTH INC. (COSM) Reports Q2 2026 Financial Results
Read moreCosmos Health Reports Full Year 2025 Results: Revenue Hits All-Time Record of $65.3M, Up 20%; Gross Profit Surges 83% to $7.9M; Gross Margin Expands 418 Basis Points; Adjusted EPS Improves 82%; Cash Position Up 10x to $3.5M; Record Growth Continues Into 2026 Across All Core Segments
Read moreCosmos Health Receives Third Consecutive Purchase Order from Pharmalink for 60,000 Units of Sky Premium Life Products in the UAE; Cumulative Orders Reach 270,000 Units, Advancing 5-Year Goal of Over 3 million Units
Read more